Tag: nAMD

Novartis’ eye drug on par with Eylea but with fewer injections

by Selina McKee | Jun 21, 2017 | News | 0

Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.

Novartis/Ophthotech eye drug fails in nAMD trials

by Selina McKee | Dec 12, 2016 | News | 0

Novartis’ plans to develop a combination of Lucentis with pegpleranib to treat patients with neovascular age-related macular degeneration (nAMD) have suffered a setback after it failed to induce better outcomes than Lucentis alone in late-stage studies.